MA45680A - Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 - Google Patents

Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123

Info

Publication number: MA45680A
Authority: MA; Morocco
Prior art keywords: bispecific antibody; proteins specifically; binding; type; binding proteins
Prior art date: 2016-07-18

Application number

MA045680A

Other languages

English (en)

Inventor

Jana Albrecht

Christian Beil

Jochen Beninga

Stéphane Guerif

Katja Kroll

Christian Lange

Wulf Dirk Leuschner

Ercole Rao

Marion Schneider

Peter Wonerow

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-18

Filing date

2017-07-17

Publication date

2019-05-22

2017-07-17 Application filed by Sanofi Sa filed Critical Sanofi Sa

2019-05-22 Publication of MA45680A publication Critical patent/MA45680A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MA045680A 2016-07-18 2017-07-17 Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123 MA45680A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16305923		2016-07-18

Publications (1)

Publication Number	Publication Date
MA45680A true MA45680A (fr)	2019-05-22

Family

ID=56507555

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA045680A MA45680A (fr)	2016-07-18	2017-07-17	Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123

Country Status (24)

Country	Link
US (1)	US20190241657A1 (fr)
EP (1)	EP3484924A1 (fr)
JP (2)	JP7071329B2 (fr)
KR (1)	KR20190028771A (fr)
CN (1)	CN109715665A (fr)
AR (1)	AR109264A1 (fr)
AU (1)	AU2017299125A1 (fr)
BR (1)	BR112019000770A2 (fr)
CA (1)	CA3030943A1 (fr)
CL (1)	CL2019000119A1 (fr)
CO (1)	CO2019001367A2 (fr)
CR (1)	CR20190072A (fr)
DO (1)	DOP2019000011A (fr)
EA (1)	EA201990321A1 (fr)
EC (1)	ECSP19011185A (fr)
IL (1)	IL264248A (fr)
MA (1)	MA45680A (fr)
MX (1)	MX2019000844A (fr)
PE (1)	PE20190514A1 (fr)
PH (1)	PH12019500122A1 (fr)
SG (1)	SG11201900400QA (fr)
TN (1)	TN2019000015A1 (fr)
TW (1)	TWI790206B (fr)
WO (1)	WO2018015340A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY191964A (en)	2015-01-23	2022-07-21	Sanofi Sa	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru)	2015-07-31	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
TN2018000266A1 (en)	2016-02-03	2020-01-16	Amgen Res Munich Gmbh	Psma and cd3 bispecific t cell engaging antibody constructs.
TWI790206B (zh) *	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN113286633A (zh) *	2018-10-30	2021-08-20	宏观基因有限公司	用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
WO2020183245A2 (fr)	2019-03-11	2020-09-17	Janssen Pharmaceutica Nv	ANTICORPS BISPÉCIFIQUES ANTI-Vβ17/ANTI-CD123
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
CN111171155B (zh) *	2020-02-05	2021-02-19	北京智仁美博生物科技有限公司	抗cd3和cd123双特异性抗体及其用途
TWI908779B (zh) *	2020-03-17	2025-12-21	美商西雅圖免疫公司	引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
CA3190987A1 (fr)	2020-08-10	2022-02-17	Janssen Biotech, Inc.	Materiels et methodes de production de lymphocytes biomodifies specifiques a un virus
WO2022056197A1 (fr)	2020-09-11	2022-03-17	Janssen Biotech, Inc.	Molécules de ciblage immunitaire et leurs utilisations
WO2022056192A1 (fr)	2020-09-11	2022-03-17	Janssen Biotech, Inc.	Méthodes et compositions pour moduler l'immunité médiée par la chaîne bêta
JP7623497B2 (ja) *	2020-12-31	2025-01-28	サノフイ	ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
SI4284512T1 (sl)	2021-01-28	2025-06-30	Regeneron Pharmaceuticals, Inc.	Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
MX2023009615A (es) *	2021-02-17	2023-08-24	Igm Biosciences Inc	Moleculas de union anti-cd123 y usos de estas.
CN113368232B (zh) *	2021-06-02	2022-08-26	上海交通大学	多特异性抗原结合蛋白及其应用
EP4380693A1 (fr) *	2021-08-06	2024-06-12	Universität Basel	Variants de protéine de surface cellulaire discernables destinés à être utilisés en thérapie cellulaire
US20230357446A1 (en)	2022-04-11	2023-11-09	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing
IL322545A (en)	2023-02-17	2025-10-01	Regeneron Pharma	Induced NK cells responding to bispecific CD3/TAA antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4361549A (en)	1979-04-26	1982-11-30	Ortho Pharmaceutical Corporation	Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hémoglobine liée à un poly(oxyde d'alkylène)
EP0272253A4 (fr)	1986-03-07	1990-02-05	Massachusetts Inst Technology	Procede pour ameliorer la stabilite des glycoproteines.
US4861719A (en)	1986-04-25	1989-08-29	Fred Hutchinson Cancer Research Center	DNA constructs for retrovirus packaging cell lines
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5278056A (en)	1988-02-05	1994-01-11	The Trustees Of Columbia University In The City Of New York	Retroviral packaging cell lines and process of using same
US6352694B1 (en)	1994-06-03	2002-03-05	Genetics Institute, Inc.	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6406696B1 (en)	1989-10-27	2002-06-18	Tolerance Therapeutics, Inc.	Methods of stimulating the immune system with anti-CD3 antibodies
JP2546544B2 (ja)	1989-10-27	1996-10-23	アーチディベラップメントコーポレイション	免疫強化を促進するための方法と組成物
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5670488A (en)	1992-12-03	1997-09-23	Genzyme Corporation	Adenovirus vector for gene therapy
NZ241119A (en)	1990-12-20	1993-06-25	Ixsys Inc	Manipulating nucleic acid to optimize the binding characteristics of the encoded binding protein
CA2156725A1 (fr)	1993-02-22	1994-09-01	Warren S. Pear	Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire
US5885573A (en)	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
FR2712812B1 (fr)	1993-11-23	1996-02-09	Centre Nat Rech Scient	Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en)	1995-01-20	2003-05-29	Rhone Poulenc Rorer Sa	Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
WO1997010354A1 (fr)	1995-09-11	1997-03-20	Kyowa Hakko Kogyo Co., Ltd.	Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997024373A1 (fr)	1995-12-29	1997-07-10	Medvet Science Pty. Limited	Antagonistes d'anticorps monoclonaux diriges contre des facteurs de croissance hematopoietiques
DE19721700C1 (de)	1997-05-23	1998-11-19	Deutsches Krebsforsch	Mutierter OKT3-Antikörper
DK1071752T3 (da)	1998-04-21	2003-10-20	Micromet Ag	CD19xCD3-specifikke polypeptider og anvendelsen deraf
WO2001066139A1 (fr)	2000-03-06	2001-09-13	University Of Kentucky Research Foundation	Procedes de degradation de cellules hematologiques embryonnaires cancereuses et composes associes
ES2672769T3 (es)	2007-08-29	2018-06-18	Sanofi	Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
EP2050764A1 (fr)	2007-10-15	2009-04-22	sanofi-aventis	Nouveau format d'anticorps bispécifique polyvalent
RU2547600C2 (ru) *	2008-10-01	2015-04-10	Эмджен Рисерч (Мьюник) Гмбх	Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
TWI588156B (zh)	2011-03-28	2017-06-21	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
PH12013502531A1 (en) *	2011-08-23	2014-01-20	Roche Glycart Ag	Bispecific t cell activating antigen binding molecules
EP4053162A1 (fr) *	2012-05-18	2022-09-07	Aptevo Research and Development LLC	Immunofusion bispécifique (ifb) de scfv se liant au cd123 et cd3
EP2839842A1 (fr)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
CN105793285A (zh) *	2013-12-10	2016-07-20	豪夫迈·罗氏有限公司	多亚基结构的亚基的结合结构域用于将药物活性实体靶向递送至多亚基结构的用途
JO3568B1 (ar) *	2014-09-05	2020-07-05	Janssen Pharmaceutica Nv	عوامل ربط cd123 واستخداماتها
CA2967426A1 (fr) *	2014-11-26	2016-06-02	Xencor, Inc.	Anticorps heterodimeriques se liant a l'antigene cd3 et a un antigene tumoral
MY191964A (en) *	2015-01-23	2022-07-21	Sanofi Sa	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
TWI790206B (zh) *	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白

2017
- 2017-07-14 TW TW106123588A patent/TWI790206B/zh not_active IP Right Cessation
- 2017-07-17 EP EP17749380.6A patent/EP3484924A1/fr not_active Withdrawn
- 2017-07-17 AR ARP170101993A patent/AR109264A1/es unknown
- 2017-07-17 CN CN201780056945.7A patent/CN109715665A/zh active Pending
- 2017-07-17 TN TNP/2019/000015A patent/TN2019000015A1/en unknown
- 2017-07-17 KR KR1020197004345A patent/KR20190028771A/ko not_active Withdrawn
- 2017-07-17 PE PE2019000065A patent/PE20190514A1/es not_active Application Discontinuation
- 2017-07-17 JP JP2019502257A patent/JP7071329B2/ja not_active Expired - Fee Related
- 2017-07-17 CA CA3030943A patent/CA3030943A1/fr active Pending
- 2017-07-17 MX MX2019000844A patent/MX2019000844A/es unknown
- 2017-07-17 US US16/318,599 patent/US20190241657A1/en not_active Abandoned
- 2017-07-17 SG SG11201900400QA patent/SG11201900400QA/en unknown
- 2017-07-17 BR BR112019000770A patent/BR112019000770A2/pt not_active IP Right Cessation
- 2017-07-17 AU AU2017299125A patent/AU2017299125A1/en not_active Abandoned
- 2017-07-17 WO PCT/EP2017/068020 patent/WO2018015340A1/fr not_active Ceased
- 2017-07-17 CR CR20190072A patent/CR20190072A/es unknown
- 2017-07-17 EA EA201990321A patent/EA201990321A1/ru unknown
- 2017-07-17 MA MA045680A patent/MA45680A/fr unknown
2019
- 2019-01-15 IL IL264248A patent/IL264248A/en unknown
- 2019-01-16 DO DO2019000011A patent/DOP2019000011A/es unknown
- 2019-01-16 CL CL2019000119A patent/CL2019000119A1/es unknown
- 2019-01-16 PH PH12019500122A patent/PH12019500122A1/en unknown
- 2019-02-15 EC ECSENADI201911185A patent/ECSP19011185A/es unknown
- 2019-02-15 CO CONC2019/0001367A patent/CO2019001367A2/es unknown
2022
- 2022-05-02 JP JP2022075664A patent/JP2022105138A/ja active Pending

Also Published As

Publication number	Publication date
DOP2019000011A (es)	2019-05-15
MX2019000844A (es)	2019-07-04
US20190241657A1 (en)	2019-08-08
AU2017299125A1 (en)	2019-03-07
TW201811830A (zh)	2018-04-01
CA3030943A1 (fr)	2018-01-25
SG11201900400QA (en)	2019-02-27
CR20190072A (es)	2019-06-25
ECSP19011185A (es)	2019-02-28
CO2019001367A2 (es)	2019-02-19
TWI790206B (zh)	2023-01-21
WO2018015340A1 (fr)	2018-01-25
PE20190514A1 (es)	2019-04-10
IL264248A (en)	2019-02-28
JP2019531701A (ja)	2019-11-07
JP7071329B2 (ja)	2022-05-18
TN2019000015A1 (en)	2020-07-15
EP3484924A1 (fr)	2019-05-22
PH12019500122A1 (en)	2019-04-15
JP2022105138A (ja)	2022-07-12
BR112019000770A2 (pt)	2019-07-02
CN109715665A (zh)	2019-05-03
EA201990321A1 (ru)	2019-06-28
KR20190028771A (ko)	2019-03-19
CL2019000119A1 (es)	2019-06-14
AR109264A1 (es)	2018-11-14

Publication	Publication Date	Title
MA45680A (fr)	2019-05-22	Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123
MA54514A (fr)	2022-03-30	Anticorps se liant à cd3
EP3512549A4 (fr)	2020-06-17	Anticorps se liant à cd3
MA51734A (fr)	2021-05-19	Anticorps se liant à gprc5d
EP3408400A4 (fr)	2019-11-27	Protéines de liaison à l'antigène se liant à pd-l1
EP3461261A4 (fr)	2019-12-04	Protéines se liant au fragment monocaténaire variable de cd3
IL263840A (en)	2019-01-31	Cd3 binding antibodies
HRP20181802T1 (hr)	2018-12-28	Protutijela koja vežu humani cd3
MA49038A (fr)	2020-02-12	Anticorps bispécifiques se liant particulièrement à pd1 et lag3
IL262437A (en)	2018-12-31	Bispecific binding proteins and uses thereof
MA71419A (fr)	2025-04-30	Anticorps se liant à egfr et cmet
MA43305A (fr)	2018-10-03	Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
IL259834A (en)	2018-07-31	Heterodimeric antibodies that bind cd3 and psma
MA41313A (fr)	2021-05-12	Anticorps de liaison de la protéine april modifiés
MA41279A (fr)	2021-04-28	Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
MA46893A (fr)	2019-10-02	Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation
ECSP18000844A (es)	2018-03-31	Anticuerpos de unión a tau
EP3604334A4 (fr)	2021-03-31	Anticorps se liant spécifiquement à muc1 et son utilisation
EP3370769A4 (fr)	2019-05-22	Anticorps se liant spécifiquement à tim-3 et leurs utilisations
EP3352760A4 (fr)	2019-03-06	Polypeptides de liaison à cd3
ECSP18000887A (es)	2018-03-31	Anticuerpos de unión a tau
MA49289A (fr)	2020-02-12	Anticorps se liant à steap-1
MA44072A (fr)	2018-10-24	Anticorps se liant spécifiquement à hla-dr et leurs utilisations
MA42821A (fr)	2018-07-25	Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
EP3514177A4 (fr)	2020-05-13	Anticorps se liant spécifiquement à pd -1 et fragment fonctionnel de celui-ci